COMMENTARY

279 Chemoprevention of Squamous Cell Carcinoma of the Head and Neck: No Time to Lose Momentum
Lori J. Wirth
See article, p. 283

RESEARCH ARTICLES

283 Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study
See commentary, p. 279

292 Tazarotene: Randomized, Double-Blind, Vehicle-Controlled, and Open-Label Concurrent Trials for Basal Cell Carcinoma Prevention and Therapy in Patients with Basal Cell Nevus Syndrome

300 Raloxifene and Antiestrogenic Gonadorelin Inhibits Intestinal Tumorigenesis by Modulating Immune Cells and Decreasing Stem-like Cells
Naveena B. Janakiram, Altaf Mohammed, Misty Brewer, Taylor Bryant, Laura Biddick, Stan Lightfoot, Gopal Pathuri, Hariprasad Gali, and Chinthalapally V. Rao

310 Excess Weight Gain Accelerates 1-Methyl-1-Nitrosourea-Induced Mammary Carcinogenesis in a Rat Model of Premenopausal Breast Cancer
Shawna B. Matthews, Zongjiaa Zhu, Weiqin Jiang, John N. McGinley, Elizabeth S. Neil, and Henry J. Thompson

319 Requirement and Epigenetics Reprogramming of Nrf2 in Suppression of Tumor Promoter TPA-Induced Mouse Skin Cell Transformation by Sulforaphane
Zheng-Yuan Su, Chengyue Zhang, Jong Hun Lee, Limin Shu, Tien-Yuan Wu, Tin Oo Khor, Allan H. Conney, Yao-Ping Lu, and Ah-Ng Tony Kong

330 Curcumin: A Double Hit on Malignant Mesothelioma
Jill M. Miller, Joyce K. Thompson, Maximilian B. MacPherson, Stacie L. Beuschel, Catherine M. Westboim, Mutlay Sayan, and Arti Shukla

341 Statins and Aspirin for Chemoprevention in Barrett’s Esophagus: Results of a Cost-Effectiveness Analysis
Sung Eun Choi, Katherine E. Perzan, Angela C. Tramontano, Chung Yin Kong, and Chin Hur

351 Class I HDACs Are Mediators of Smoke Carcinogen–Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer
Seth A. Brodie, Ge Li, Adam El-Kommos, Hyunseok Kang, Suresh S. Ramalingam, Madhusmita Behera, Khanjan Gandhi, Jeanne Kowalski, Gabriel L. Sica, Fadlo R. Khuri, Paula M. Vertino, and Johann C. Brandes

362 The UK Lung Screen (UKLS): Demographic Profile of First 88,897 Approaches Provides Recommendations for Population Screening
Fiona E. McDonald, Ghasem Yasdegahr, David R. Baldwin, Anand Devaraj, Kate E. Brain, Tim Eisen, John A. Holmants, Martin Ledson, Nicholas Screaton, Robert C. Rintoul, Christopher J. Hands, Kate Lifford, David Whynes, Keith M. Kerr, Richard Page, Mahesh Parmar, Nicholas Wald, David Weller, Paula R. Williamson, Jonathan Myles, David M. Hansell, Stephen W. Duffy, and John K. Field

CORRECTION

372 Correction: Interaction of Fatty Acid Genotype and Diet on Changes in Colonic Fatty Acids in a Mediterranean Diet Intervention Study
Estrogen plays an important role in colon tumorigenesis. Studies show that selective estrogen receptor modulators, such as raloxifene, suppress tumor growth. However, gonadorelin, possessing estrogen-modulatory effects, has not been tested on tumor growth. The preventive effects of raloxifene and gonadorelin were studied in female Apc\(^{Min}\) mice. Mice treated with raloxifene and gonadorelin showed colon tumor inhibition of 80% and 75%, respectively. As well, these treated tumors showed significantly increased natural killer (NK) cells and chemokines required for NK cells as well as decreased inflammatory genes and cancer stem-like cells (Lgr 5, EpCAM, CD44/CD24). The cover micrograph (60×) depicts the immunohistofluorescence of NK cell receptors (red) and nuclei (blue) in intestinal tumors from Apc\(^{Min}\) mice treated with raloxifene and gonadorelin (~4-fold increase; P < 0.002). Both drugs were effective in suppressing tumor growth albeit with different mechanisms. These observations show that either suppression of endogenous estrogen levels (by gonadorelin) or modulation of estrogen receptor (by raloxifene) dramatically suppress small intestinal and colonic tumor formation in female Apc\(^{Min}\) mice and supports the concept of chemoprevention by these agents in reducing endogenous levels of estrogen or modulating ER signaling. See article by Janakiram and colleagues (beginning on page 300) for more information.